Immune Checkpoint Inhibitors (ICIs) are successful in 40% of cancer patients but are invasive and time-consuming. Scientists at Israel’s Technion Institute have developed a tool that predicts the response based on the metabolic activity in the immune system cells. (See also here previously)
https://technionuk.org/news-post/new-tool-determines-cancer-patient-response-to-immunotherapy/